One key way DNA sequencing is being used to study cancer is through the application of Next-Generation Sequencing (NGS), which enables detailed genetic profiling of tumours. This is reshaping diagnostics, prognostics, and personalised treatment. Applications of DNA Sequencing in Cancer Research: Identification of Driver Mutations DNA sequencing allows researchers to detect mutations that initiate or drive cancer progression, such as BRCA1/2 in breast and ovarian cancer, or EGFR and KRAS in lung cancer. Understanding these mutations helps stratify patients for targeted therapies. Predicting Treatment Response Sequencing can reveal whether a patient is likely to respond to specific therapies. For example, tumours with high tumour mutational burden (TMB) or microsatellite instability (MSI) are more likely to respond to immunotherapies. Monitoring Resistance Mechanisms Longitudinal sequencing (e.g., via liquid biopsy) enables clinicians to observe the evolution of cancer during treatment. This helps in identifying resistance mutations, such as EGFR T790M, and adjusting therapy accordingly. Early Detection and Minimal Residual Disease (MRD) Circulating tumour DNA (ctDNA) analysis, informed by sequencing, is being used for early detection and to monitor minimal residual disease after treatment-key for recurrence prediction. Development of Novel Therapies Sequencing data contributes to drug development by identifying new mutational targets and understanding tumour biology in depth. In summary, DNA sequencing is not only deepening our understanding of cancer's genetic complexity but also enabling clinicians to deliver more precise, responsive, and personalised care to patients.
One way DNA sequencing is being used to study cancer is by identifying genetic mutations that drive tumor growth. I recently came across a study where researchers used whole-genome sequencing to analyze the DNA of patients with breast cancer. By identifying specific mutations in the tumor's genetic code, they were able to pinpoint which mutations were causing the cancer to grow more aggressively. This information led to the development of targeted therapies that directly target those specific mutations, rather than using a one-size-fits-all approach. For example, a drug was developed that specifically inhibits the mutated gene responsible for resistance to treatment in some breast cancer patients. The results have been promising, with patients showing improved response rates. DNA sequencing is providing crucial insights that are shaping more personalized, effective treatments, offering hope for better outcomes in cancer care.
DNA sequencing is transforming cancer research by identifying genetic mutations linked to various cancer types. Next-generation sequencing (NGS) profiles tumor genomes, revealing actionable mutations that guide personalized treatments. For example, in non-small cell lung cancer (NSCLC), sequencing tumor DNA helps identify key mutations in genes like EGFR and ALK, which inform targeted therapies for better patient outcomes.